a public good project by the
Synthesis
Company
of California

© 2026

Daniel L. Menezes | doi.page

0 works0 citations0 h-index

Daniel L. Menezes

Bristol-Myers Squibb (United States)(US)Bristol-Myers Squibb (Sweden)(SE)

Publications by Year

Research Areas

Acute Myeloid Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Histone Deacetylase Inhibitors Research, Chronic Myeloid Leukemia Treatments, Heat shock proteins research

Most-Cited Works

→ Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor(2011)525 cited
→ Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer(2011)249 cited
→ Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study(2020)177 cited
→ In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models(2005)173 cited
→ Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study(2019)127 cited
→ A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-Function(2014)101 cited

→ The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo(2012)

86 cited

→ Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial(2017)82 cited

→ Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes(2021)76 cited

→ Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status(2022)62 cited